We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Andrx, Amphastar Pen Deal For Generic Lovenox

Law360 (May 5, 2005, 12:00 AM EDT) -- Drug maker Andrx Corp. has entered into a marketing rights agreement with Amphastar Pharmaceuticals for a generic version of Sanofi-Aventis’ Lovenox, a treatment for deep vein thrombosis.

Amphastar's generic version is currently the subject of a patent infringement lawsuit brought by Aventis and is under a 30-month stay that expires in February 2006.

In December, Aventis’ bid for a reissuance of the U.S. patent for best-selling anti-blood clotting drug Lovenox finally won approval from the U.S. Patent and Trademark office.

The USPTO previously rejected two attempts...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.